The novel recombinant EGFR-targeting β-defensin Ec-LDP-hBD1 displays both selectivity and enhanced cytotoxicity against cancer cells by inducing mitochondria-mediated apoptosis and exhibiting high therapeutic efficacy against EGFR-expressing carcinoma xenografts. Here, EGFR is linked to carcinoma.